Glucocorticoid receptor–SRY-box transcription factor 9 protein–protein interaction complex (GR–SOX9 complex)

The Glucocorticoid receptor (GR)–SRY-box transcription factor 9 (SOX9) protein–protein interaction complex is a transcriptional regulatory unit essential for skeletal development and cartilage maintenance. This complex forms when the ligand-activated glucocorticoid receptor (NR3C1) physically associates with SOX9, a master transcription factor for chondrogenesis, to synergistically activate genes like COL2A1 (Collagen Type II Alpha 1 Chain) [PMID: 24553142]. In orthopedic medicine, this interaction is a focal point for understanding how glucocorticoids exert pro-anabolic effects on chondrocytes, which is relevant for treating osteoarthritis and cartilage degeneration [PMID: 21835247]. Beyond skeletal biology, the GR–SOX9 interaction has been identified as a mechanism of therapeutic resistance in advanced prostate cancer, where GR can substitute for the androgen receptor and drive SOX9-dependent lineage plasticity [PMID: 28848083]. Pharmacological modulation of this complex aims to either stabilize the interaction to promote tissue repair or disrupt it to overcome drug resistance in oncology. However, therapeutic targeting is challenged by the pleiotropic effects of GR and the necessity for precise, tissue-specific delivery to avoid systemic metabolic and bone-related toxicity [PMID: 25601555]. The complex represents a paradigm for how nuclear receptors and lineage-specific transcription factors integrate signals to control cell identity.

Other names

NR3C1–SOX9 complexGlucocorticoid receptor–SOX9 interactionGR–SOX9 PPI complex

Ligand-induced recruitment of the glucocorticoid receptor to SOX9-binding sites to co-regulate target gene expression or modulate lineage plasticity.